BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p)
Data de publicación
2015Título da revista
Journal Of Clinical Oncology
Tipo de contido
Publicación de congreso